Shandong Linglong Tire Co., Ltd.

Magellan Pharma Co. Ltd.

Yantai Medgenn Ltd.

Bing Zhou

Jing Jiang

Yu Zhou

Yongzhang Luo

Zhuobing Zhang

Li Li

Yong Xie

Tire

This invention relates to the biotechnology area, and provides a kind of TRAIL chimeric protein, DNA sequence encoding this chimeric protein, vectors comprising this DNA, host cells or transgenic animals that contain one of the vectors, and preparation methods for the said chimeric protein and its applications. The said TRAIL fusion protein from the N to C terminal comprises human leucine zipper sequence, human TRAIL protein, human TRAIL extracellular domain or a fragment thereof. The chimeric protein has significantly enhanced stability, prolonged half-life in animals, increased efficacy and thus has broad application future.

Therapeutic TRAIL fusion protein and preparation and use thereof

The invention relates to endostatin protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.

N-terminal modified recombinant human endostatin and its production

Growing community of inventors

Yantai, China

Bing Zhou